Showing results (1-10 of 299) with videos related to
Sort By:
Pageof 30
American Health & Drug Benefits|February 5, 2020
Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based TestingJoshua A Roth, Theo deVos, Scott D RamseyThe Oncologist|October 21, 2015
Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate CancerJoshua A Roth, Scott D Ramsey, Josh J CarlsonThe Oncologist|April 9, 2014
Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancerJoshua A Roth, Paul Billings, Scott D Ramsey, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 3, 2010
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practiceDavid L Veenstra, Joshua A Roth, Louis P Garrison, et al.The Oncologist|March 1, 2017
Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and OpportunitiesJoshua A Roth, Bernardo H L Goulart, Arliene Ravelo, et al.Bone Marrow Transplantation|June 1, 2020
Value and affordability of CAR T-cell therapy in the United StatesSalvatore Fiorenza, David S Ritchie, Scott D Ramsey, et al.Public Health Genomics|April 22, 2010
Stakeholder perspectives on a risk-benefit framework for genetic testingJoshua A Roth, Louis P Garrison, Wylie Burke, et al.Journal of Comparative Effectiveness Research|March 21, 2014
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancerJoshua A Roth, Mark E Bensink, Paul V O'Donnell, et al.Journal of Medical Economics|December 18, 2020
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancerJoshua A Roth, Yong Yuan, Megan Othus, et al.Journal of Oncology Practice|May 7, 2015
Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in MedicareJoshua A Roth, Sean D Sullivan, Bernardo H L Goulart, et al.Pageof 30